Free tool
FAERS Monitor: Orilissa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210450 or its brand name (Orilissa, Elagolix Sodium). Reports on generic versions are filed under their own applications.
Reports
3,729
Serious
1,319
35% of reports
Hospitalization
321
Death reported
6
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hot flush471
- pain437
- nausea327
- endometriosis304
- headache277
- drug ineffective253
- depression214
- arthralgia200
- anxiety163
- insomnia151
- suicidal ideation148
- adverse drug reaction140
- fatigue137
- surgery136
- mood swings115
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 49 |
| 2019 | 930 |
| 2020 | 1,090 |
| 2021 | 517 |
| 2022 | 700 |
| 2023 | 223 |
| 2024 | 121 |
| 2025 | 75 |
| 2026 | 24 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,430 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endometriosisSignal | 304 | 384.0 | 343.4 | 108,399 |
| hot flushSignal | 471 | 35.5 | 32.6 | 15,698 |
| mood swingsSignal | 115 | 20.4 | 17.1 | 2,100 |
| surgerySignal | 136 | 13.1 | 11.1 | 1,510 |
| suicidal ideationSignal | 148 | 9.1 | 7.8 | 1,067 |
| adverse drug reactionSignal | 140 | 8.8 | 7.5 | 963 |
| depressionSignal | 214 | 5.3 | 4.7 | 752 |
| painSignal | 437 | 4.0 | 3.7 | 1,015 |
| anxietySignal | 163 | 3.2 | 2.8 | 252 |
| insomniaSignal | 151 | 3.2 | 2.7 | 229 |
| arthralgiaSignal | 200 | 2.7 | 2.4 | 219 |
| headacheSignal | 277 | 2.5 | 2.2 | 254 |
| nauseaSignal | 327 | 2.3 | 2.1 | 257 |
| drug ineffective | 253 | 1.1 | 1.0 | 2 |
| fatigue | 137 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.